CAR T Cells with a Dominant-Negative TGFβ Receptor Are Safe and Feasible

Skip Nav Destination

Article navigation

Research Watch| June 02 2022

Online Issn: 2159-8290

Print Issn: 2159-8274

2022

American Association for Cancer Research

Cancer Discov (2022) 12 (6): 1406.

Abstract

PSMA-targeting CAR T cells with a dominant-negative TGFβR show safety and feasibility in prostate cancer.

2022

American Association for Cancer Research

You do not currently have access to this content.

Don't already have an account? Register

You could not be signed in. Please check your email address / username and password and try again.